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Engineering the lagellar type III secretion 
system: improving capacity for secretion 
of recombinant protein
Charlotte A. Green1,5, Nitin S. Kamble1, Elizabeth K. Court1, Owain J. Bryant3, Matthew G. Hicks1, 
Christopher Lennon4, Gillian M. Fraser3, Phillip C. Wright2 and Graham P. Staford1* 
Abstract 
Background: Many valuable biopharmaceutical and biotechnological proteins have been produced in Escherichia 
coli, however these proteins are almost exclusively localised in the cytoplasm or periplasm. This presents challenges 
for puriication, i.e. the removal of contaminating cellular constituents. One solution is secretion directly into the sur-
rounding media, which we achieved via the ‘hijack’ of the lagellar type III secretion system (FT3SS). Ordinarily lagellar 
subunits are exported through the centre of the growing lagellum, before assembly at the tip. However, we exploit 
the fact that in the absence of certain lagellar components (e.g. cap proteins), monomeric lagellar proteins are 
secreted into the supernatant.
Results: We report the creation and iterative improvement of an E. coli strain, by means of a modiied FT3SS and a 
modular plasmid system, for secretion of exemplar proteins. We show that removal of the lagellin and HAP proteins 
(FliC and FlgKL) resulted in an optimal prototype. We next developed a high-throughput enzymatic secretion assay 
based on cutinase. This indicated that removal of the lagellar motor proteins, motAB (to reduce metabolic burden) 
and protein degradation machinery, clpX (to boost FT3SS levels intracellularly), result in high capacity secretion. We 
also show that a secretion construct comprising the 5′UTR and irst 47 amino acidsof FliC from E. coli (but no 3′UTR) 
achieved the highest levels of secretion. Upon combination, we show a 24-fold improvement in secretion of a 
heterologous (cutinase) enzyme over the original strain. This improved strain could export a range of pharmaceuti-
cally relevant heterologous proteins [hGH, TrxA, ScFv  (CH2)], achieving secreted yields of up to 0.29 mg L
−1, in low cell 
density culture.
Conclusions: We have engineered an E. coli which secretes a range of recombinant proteins, through the FT3SS, 
to the extracellular media. With further developments, including cell culture process strategies, we envision further 
improvement to the secreted titre of recombinant protein, with the potential application for protein production for 
biotechnological purposes.
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Background
A persistent goal of biotechnology is to produce recom-
binant protein at reduced cost, while maintaining 
high product quality and yield. For many protein bio-
logics, production in prokaryotes (chiely in E. coli) is 
favoured. Major advantages include fast growth to high 
cell densities on cheap carbon sources, and simple scale 
up [1, 2]. However, as in many industrial biotechnol-
ogy (IB) processes, downstream processing accounts 
for a high proportion of costs [3–5]. If protein prod-
uct was secreted by the expression organism into the 
growth media, these costs could be reduced, as purii-
cation could be simpliied, i.e. eliminating the need to 
lyse cells, or to remove cellular contaminants, which 
can compromise product purity, and may elicit an 
immune response in humans (e.g. lipopolysaccharide 
in E. coli) [6–8]. In addition, product yield and quality 
may be increased, as secretion would bypass cytoplas-
mic and periplasmic proteases. Extracellular secretion 
may also improve protein folding and solubility, while 
also reducing the formation of inclusion bodies, thus 
increasing product yield and quality [9–12].
Secretion of heterologous protein in E. coli has been 
utilised, however the majority of work concerns secre-
tion into the periplasm via Sec or Tat-dependent sys-
tems [10]. While this strategy can yield titres in the 
mg L−1 range (e.g. 30 mg L−1 human growth hormone 
[13], 60  mg  L−1 GFP [14]), this is only achieved fol-
lowing puriication from the periplasm. Alternatively 
extracellular localisation of protein can be achieved In 
E. coli without directed secretion to the extracellular 
space via strategies that make use of ‘leaky strains’ [15], 
where heterologous proteins are fused to a secretion 
tag (for example ompA, ompC, pelB [16, 17]), to enable 
directed secretion to the periplasm, followed by leak-
ing into the supernatant. While titres may be favour-
able, the presence of additional periplasmic proteins 
adds complexity to puriication, e.g. while 550  mg  L−1 
cell culture of lipase B tagged with the pelB signal 
sequence was found in the extracellular fraction of E. 
coli, high concentrations of periplasmic proteins were 
also detected, and only one-ifth of the product was 
able to be recovered [18]. To date, true secretion (i.e. 
to the extracellular space via a deined secretion sys-
tem, rather than through leaking or lysis) of heterolo-
gous protein by prokaryotes has been achieved at up to 
approximately 50  mg  L−1, in organisms such as Bacil-
lus and Pseudomonas [19–21], as opposed to the g L−1 
titres achieved in eukaryotes such as Pichia pastoris 
[22]. In E. coli, attempts to secrete proteins directly 
into the media have been limited, with evidence of 
low levels (i.e. 1  µg to 1  mg  L−1 of heterologous pro-
tein) via type I secretion system (T1SS) using either 
the Haemolysin or lipase transporting ABC transporter 
systems [23–28]. Another option for direct secretion 
into the media, is the bacterial lagellar type III secre-
tion system, which has been utilised in E. coli [29–32], 
Bacillus [20] and Salmonella enterica sv. Typhimurium 
[33–36]. In addition, secretion of up to 30 mg L−1 of a 
range of polymers [37], such as tropo-elastin and spider 
silk, have also been reported using the injectisome type 
III secretion system of S. enterica [37–39].
In this report we focus on the E. coli FT3SS, due to a 
preference in IB for both E. coli, and non-pathogenicity 
associated secretion systems. E. coli have 4–10 lagel-
lum of around 20  μm in length, each comprising of up 
to 30,000 lagellin (FliC) monomers [40–43]. he FT3SS, 
despite having evolved to build a lagellum and provide 
motility to the cell, is efectively an eicient protein 
secretion machineable to assemble a multi-component 
structure composed of several thousand subunits on its 
surface. Proteins initially assemble at the inner mem-
brane, resulting in a pore of about 2.0  nm diameter, 
through which the majority of the remaining lagellar 
proteins are exported, unfolded, to the distal end of the 
existing lagellar structure [44]. herefore in the context 
of biotechnology, the FT3SS may provide a one step, high 
capacity route for protein export.
he basic lagellar structure is comprised of the basal 
body (motor and secretion apparatus), hook (univer-
sal joint), and ilament (propeller), which are assembled 
in an ordered manner, controlled by well-understood 
checkpoints [45]. One key feature is the existence of a 
lagella master regulator  (FlhD4C2-class I) that activates 
class II lagellar genes. hese class II genes transcribe the 
basal body and FT3SS apparatus, along with the sigma 
factor FliA, which in turn promotes the transcription of 
the class III genes (for the ilament, motor, hook associ-
ated and hook proteins, along with the chaperone and 
chemotaxis proteins) [46, 47]. Furthermore, transcription 
is also coupled to assembly, as levels of FliA are modu-
lated by the anti-sigma factor (FlgM), which is secreted 
upon hook-completion [48–50]. Additionally, given the 
energetic cost of motility, expression of the master reg-
ulator is modulated by many environmental cues that 
alter gene expression of the flhDC operon or activity of 
 FlhD4C2 [51, 52].
Here, we aimed to capitalise on the fact that upon 
mechanical shearing or breakage, lagellar continue to 
secrete unfolded FliC monomers which are transported 
to the distal growing tip, allowing regrowth under the 
FliD cap [53–55]. In addition, in the absence of the FliD 
cap, or other structural proteins (e.g. FlgKL), secretion 
of FliC monomers into the media without polymerisa-
tion occurs [56, 57]. In addition, the N-terminal secretion 
signals of FT3SS subunits are well characterised and have 
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been exploited to direct non-FT3SS subunits for secre-
tion through the FT3SS in E. coli [29–32] and (their close 
relatives) Salmonella [34–36]. We aimed to develop an 
improved, modular FT3SS E. coli strain for high yield-
ing secretion of a range of therapeutic recombinant pro-
teins. Our eventual aim is to surpass the secretion titres 
reported in other E. coli secretion systems, by achieving 
extracellular secreted titres in the high mg L−1 range. We 
hope to accomplish this using controlled secretion to the 
extracellular space, combined with the absence of cellu-
lar contaminants. Here we report progress towards these 
targets via strain development, secretion signal optimisa-
tion, rigorous use of controls, and development of a high-
throughput assay to measure FT3SS secretion.
Results
Establishing a prototype FT3SS secretion strain 
and deining optimal parameters for protein expression 
and secretion
In this study we used E. coli MC1000 as the parent strain, 
partly for biosafety given its leucine auxotrophy, but also 
given the presence of an IS5 insertion sequence upstream 
of flhD. his reduces negative transcriptional regula-
tion on flhDC, by disrupting promoter binding sites for 
the negative regulators LrhA and OmpR (for annotated 
sequence see Additional ile 1: Fig. S1) [58–60]. Previous 
studies of FT3SS dependent protein secretion in E. coli 
employed a ΔfliD ‘cap-less’ strain [29–31, 36]. We also 
considered alternative strategies, given the potential for 
this strain to inluence and suppress  FlhD4C2 activity via 
post-translational protein–protein interactions of the 
FlhDC complex with FliT (the chaperone of FliD) [61, 
62]. Speciically, we created a ‘HAP-less’ (ΔflgKL) strain, 
which would not incur feedback on  FlhD4C2
−, but would 
theoretically decouple secretion from assembly, i.e. as 
opposed to the ΔfliD strain where more free FliT would 
potentially repress  FlhD4C2 activity, and thus lagellar 
gene expression [61]. In addition, it has also been estab-
lished that in ΔflgKL mutants, unpolymerised FliC mono-
mers are secreted into the media, rather than assembling 
into a ilament [56]. To lessen competitive secretion, 
strains also lacked fliC. We found that the HAP-less 
and cap-less strains displayed identical growth curve 
parameters (Additional ile  1: Fig. S2). We then com-
pared their ability to export a 39 kDa shortened version 
of FliC that lacked the central D3 domain (residues 191–
283) so that it could be easily distinguished from native 
FliC. his secretion substrate was termed FliC-ΔD3 and 
was inserted into plasmid pTrc99a-FF to create pTrc-
FliC-ΔD3, and expressed by addition of IPTG. his sub-
strate was eiciently secreted (Fig. 1) and also produced 
a fully motile strain when provided in trans in a ΔfliC 
strain (Additional ile 1: Fig. S3).
As shown in Fig.  1a, b when FliC-ΔD3 was expressed 
with induction using 0.05  mM IPTG, we observed 
approximately twofold more FliC-ΔD3 (on average 
7.4  mg  L−1) in the secreted fraction of the HAP-less 
strain in comparison to the cap-less. Notably, we also 
observed increased amounts of FliC intracellularly in 
the HAP-less strain (Fig. 1a, c) but found overall that the 
HAP-less strain was 1.3 times more eicient at secret-
ing protein (secreted FliC-ΔD3 as a function of total 
FliC-ΔD3, i.e. 7.4  mg  L−1 divided by 98  mg  L−1 for the 
HAP-less strain). Based on the absence of additional pro-
teins in the cell supernatant (Fig.  1a—Coomassie), we 
infer that the improved titre of secreted FliC-ΔD3 was 
due to FT3SS secretion, as cell lysis was not prevalent in 
either of these strains. We therefore used the HAP-less, 
ΔfliC ΔflgKL strain in subsequent experiments as our 
prototype FT3SS secretion strain.
Before further experimentation, we deined optimal 
parameters for expression and production of proteins via 
the FT3SS-assessing that the optimal  OD600 for harvest 
of cells for maximal secretion of FliC-ΔD3, is between 
an  OD600 of 1 and 2, i.e. the mid-late exponential phase 
(Fig. 2a and inset). We then examined the efects of vary-
ing the inducer (IPTG) concentration on expression and 
secretion of FliC-ΔD3. We harvested cells at an  OD600 
of 1.0 and show that 0.05 mM IPTG produced the high-
est concentration of both intracellular and secreted 
FliC-ΔD3 (Fig.  2b), therefore this procedure forms the 
basis of experiments.
Preliminary improvement of the FT3SS prototype using 
native substrates
To establish whether secretion via the FT3SS could be 
improved from this basal level, we considered a series of 
mutations that might boost overall lagellar gene expres-
sion. We then compared their efect on secretion to a 
number of negative controls, to establish the absolute 
speciicity of this system. As seen in Fig. 3a, b, use of an 
flhDC null mutant, with no FT3SS present, resulted in 
complete lack of FliC-ΔD3 secretion even when overpro-
duced in the cytoplasm (by addition of 1 mM IPTG). In 
parallel we also tested secretion of FliC-ΔD3 in a (ΔfliC 
ΔflgKL) ∆flgDE strain, in which secretion of ‘late’ ila-
ment substrates (i.e. FliC) is abrogated due to the absence 
of substrate speciicity switching [57, 63], and observed a 
complete lack of secretion in this strain. Further to these 
controls, we also tested for the presence of the strictly 
cytoplasmic, GroEL chaperonin protein. Aside from a 
negligible amount in the ∆flhDC strain, the cytoplasmic 
contaminant GroEL was absent in secreted fractions 
(Fig. 3c). his demonstrates that cell lysis was not preva-
lent, and that the two secretion strains are no more ‘leaky’ 
that the negative control strains. Together, this conirmed 
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that the presence of FliC-ΔD3 monomers in the secreted 
fraction was due to targeted FT3SS secretion alone.
We then examined the efect of mutations that might 
upregulate lagellar gene expression. Our initial target 
was the protein quality control protein, ClpX, a com-
ponent of the ClpXP protease complex which acts on 
 FlhD4C2 [64]. In previous studies the removal of clpX in 
Salmonella and enterohaemorrhagic E. coli resulted in an 
accumulation of  FlhD4C2, an increase in the amount of 
FliC subunits secreted, and increased cell motility [65–
67]. Here we show that the removal of clpX from wildtype 
E. coli MC1000 cells resulted in an increase in ilament 
proteins and increased motility (Additional ile  1: Fig. 
S4a–d). he removal of clpX from the prototype strain 
resulted in an increase in both intracellular and secreted 
FliC-ΔD3 (Fig.  3a, b). he secretion eiciency (secreted 
protein as a proportion of the total (intracellular and 
secreted) protein) did not alter, however we did meas-
ure a 1.6-fold average increase in the titre of secreted 
protein, and a maximum estimated secretion of 34  mg 
FliC-ΔD3  L−1 culture medium achieved from ΔfliC 
ΔflgKL ∆clpX (calculated by comparison to a FliC-ΔD3 
standard). We also noted that ΔfliC ΔflgKL ΔclpX cells 
were on average 1.2 times longer (p < 0.001. t-test) than 
ΔfliC ΔflgKL cells, with a higher abundance of very long 
cells (> 0.8  µm) (Additional ile  1: Fig. S4e–g). As we 
detected signiicantly more (p < 0.05) FlhA in ΔclpX cells 
(Fig.  5c), this may suggest that elongated cells harbour 
a larger number of FT3SS basal bodies, thus allowing 
increased secretion, though we have no experimental evi-
dence for this at this stage. Of note is that we also pro-
duced a ΔfliC ΔflgKL ΔdksA strain, which in contrast to 
what was anticipated based on published literature [68, 
69], did not result in any noticeable increases in FT3SS 
secretion. As a result, we moved on with the ΔfliC ΔflgKL 
∆clpX strain as a Mark II FT3SS strain to test additional 
strain modiications.
Development of a prototype secretion plasmid 
and high‑throughput assay to measure secretion
In order to move towards our goal of production and 
secretion of heterologous proteins via the FT3SS, we 
designed and tested a synthetic prototype modular vec-
tor. his contained elements aimed at optimal secretion 
of proteins via the FT3SS, alongside their subsequent 
detection and ultimately puriication (FLAG and Strepta-
vidin, TEV protease. See Additional ile 1: Fig. S5). hese 
were produced as plasmids in the IP-Free pJEXpress 
backbone (DNA2.0), with the irst 47 amino acids of FliC 
(the secretion signal [70]), the fliC 5′UTR (which also 
harbours the native fliC promoter, thus allowing both 
T5 based-IPTG inducible, and lagellar mediated (class 
III, via FliA [71, 72]) gene expression), alongside the fliC 
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Fig. 1 Comparison of secretion capacity in the HAP-less and cap-less 
strains. E. coli MC1000 ΔfliC ΔflgKL (ΔCKL) and ΔfliCD containing the 
plasmid pTrc-FliC-ΔD3 were grown in LB supplemented with 0.05 mM 
IPTG, and harvested at  OD600 1.5. Samples which represented 
either 25 µL or 400 µL culture media were loaded for SDS-PAGE, 
for intracellular and secreted protein respectively. a Representative 
images showing the secreted fractions following Coomassie staining, 
and the intracellular fractions following immunoblotting using an 
anti-lagellin (H48) antibody and a HRP secondary. A FliC-ΔD3 protein 
standard (S) was also included, to allow quantiication of protein 
concentration by densitometry (b, c). Quantiications for biological 
triplicates, ± SE and individual data points shown, *p < 0.05
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3′UTR, both of which have been implicated in inluenc-
ing secretion through the FT3SS [30, 31]. Finally, restric-
tion enzyme sites were incorporated throughout to allow 
modular modiication of the secretion construct; notably 
EcoRI and PstI sites allow for the insertion of any cargo 
gene for secretion.
We initially chose a heterologous protein target for 
secretion which was non-bacterial, commercially relevant 
and assayable. his enabled ease of screening for secre-
tion via an activity assay, thus facilitating higher through-
put screening for improved FT3SS strains. Our choice 
was the well-characterised 20.8  kDa cutinase from the 
unicellular fungus Fusarium solani, which had previously 
been expressed in E. coli intracellularly [73, 74], and for 
which a well-established activity assay based on its ester-
ase activity is known [75]. Advantageously, cutinase is 
also relevant in IB processes, e.g. degradation of plastics 
[76, 77]. An E. coli codon optimised cutinase was synthe-
sised  (GeneArt®) and inserted into the pJex-fliC47-empty 
plasmid resulting in pJex-fliC47-cutinase, which is pre-
dicted to yield a 30.6 kDa peptide.
Following expression of pJex-fliC47-cutinase in the 
∆fliC ∆flgKL strain, both intracellular and secreted 
cutinase were detected, via the secretion construct 
incorporated FLAG tag (Fig.  4a). We next developed a 
simple luorimetric secretion assay, based on cleavage 
of 4-methylumbelliferyl butyrate (MUB) by cutinase to 
yield a luorescent 4-methylumbelliferone (4-MU) [78]. 
Cell-free supernatant was mixed with MUB in the pres-
ence of an appropriate bufer, and release of 4-MU was 
measured. his could be qualitatively observed on a UV-
transilluminator to allow quick visual screening (Fig. 4b). 
We also established conditions for a quantitative plate-
reader based version of the assay (excitation 302  nm, 
emission 446  nm). To test the speciicity of the assay, 
pJex-fliC47-cutinase was transformed into negative con-
trol strains (∆flhDC and ΔfliC ΔflgKL ∆flgDE) as in Fig. 3. 
After subtraction of background MUB cleavage no activ-
ity was detected in strains containing pJex-fliC47-empty 
or LB only controls (Fig.  4c). Absence of secretion was 
veriied by immunoblotting of the same samples (Fig. 4d). 
Reassuringly, we observed increased concentrations of 
secreted cutinase (twofold higher AU) in the Mark II 
ΔfliC ΔflgKL ΔclpX strain compared to the ΔfliC ΔflgKL 
prototype strain. We used this assay to detect a range of 
concentrations of secreted cutinase (0.04–0.20  mg  L−1), 
and note that the assay could detect cutinase concentra-
tions is excess of this. With the assay established, it was 
possible to screen a larger number of strains and secre-
tion signal variants, with the aim of generating a higher 
capacity, Mark III secretion strain.
Use of the high‑throughput cutinase screen to establish 
an optimised secretion strain
he MUB-cutinase assay was next utilised to assess the 
secretion capacity of a number of alternative FT3SS 
secretion strains. hese were engineered to upregulate 
lagellar expression, or reduce metabolic burden via the 
deletion of redundant genes. hese included the clpX 
knockout strain outlined previously, and three additional 
targets: ∆flgMN (FlgM a negative regulator of class III la-
gellar gene regulation, and FlgN chaperone for FlgK and 
regulator of FlgM [50, 79, 80]), ∆fliDST (FliT—an anti-
FlhD4C2 factor and FliST—chaperones of FliCD [61, 81]) 
and ∆motAB (MotAB responsible for energising lagellar 
rotation, but not required for secretion [82, 83]). Follow-
ing their construction and establishing that growth of all 
strains was comparable to ∆fliC ∆flgKL (Additional ile 1: 
Fig. S6), the supernatant was analysed for the presence 
of cutinase via the MUB luorescence assay (Fig. 5a). Of 
all the combinations tested, only ∆fliC ∆flgKL ∆motAB 
∆fliDST and ∆fliC ∆flgKL ∆clpX ∆motAB resulted in 
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Fig. 2 Optimisation of cell culture induction and harvesting 
procedure for the FliC-ΔD3 protein secretion assay. The ‘prototype’ E. 
coli MC1000 ΔfliC ΔflgKL (ΔCKL) containing the plasmid pTrc-FliC-ΔD3 
was grown in 100 mL lask cultures in LB and either a supplemented 
with 0.05 mM IPTG and harvested every hour or b supplemented 
with 0, 0.05, 0.1, 0.5 or 1 mM IPTG and harvested at  OD600 1.0. 
FliC-ΔD3 was detected by immunoblot as described in Fig. 1a. 
Samples which represented either 25 µL or 300 µL culture media 
were loaded for SDS-PAGE for intracellular and secreted protein 
respectively. Densitometry analysis allowed quantiication of secreted 
protein, throughout the growth curve. This was repeated to ensure 
that this corroborated with the general trend
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a signiicant improvement to secretion, in comparison 
to the original ∆fliC ∆flgKL strain: 1.64- and 1.67-fold 
respectively, (p < 0.05 and < 0.01). To ensure that poor 
secretion was not a factor of poor cutinase expression, 
the presence of intracellular cutinase in all strains was 
conirmed with immunoblotting (Fig. 5a—intracellular).
Having identiied high capacity secretion strains that 
could secrete active fungal cutinase, we now wished to 
test a human recombinant protein: an E. coli codon opti-
mised version of the gene encoding human ‘CH2’  (CH2) 
ScFv antibody fragment (23  kDa, donated by J. Pand-
hal, University of Sheield [84, 85]), which is used as an 
adjuvant in human antibody drugs. his was inserted 
into our modular secretion vector. We compared secre-
tion of  CH2 and the native substrate, FliC-ΔD3, in the 
most promising secretion strains, and observed (similarly 
to cutinase) improved secretion in ΔfliC ΔflgKL ∆clpX 
∆motAB strain: 2.57×  (CH2) and 3.75× (FliC-ΔD3) over 
that observed for the prototype strain (Fig. 5b). For both 
substrates this amounted to a 2.8-fold improvement 
to secretion eiciency. In contrast, the ΔfliC ΔflgKL 
∆motAB ∆fliDST strain did not perform in a similar 
manner to cutinase, when secreting  CH2 and FliC-ΔD3, 
with no improvement to secretion over the prototype. 
We thus concentrated on ΔfliC ΔflgKL ∆clpX ∆motAB, as 
a Mark III strain.
To gain more information on the varying success of 
these two strains, we used an antibody directed against 
the FlhA protein (which is present as part of the FT3SS 
export apparatus) as a proxy indicator of the number of 
lagellar export apparatus in the cell population. Since its 
gene expression is under the control of  FlhD4C2, FlhA is 
also an indicator of total lagellar gene expression. Whole 
cell lysates were examined by immunoblot and quanti-
ied by densitometry analysis (Fig.  5c). Mutant strains 
representing the individual knockout strategies were also 
included as controls. Overall, these data indicate that 
deletion of clpX results in an increase in FlhA levels by 
approximately 1.5-fold in both the ΔfliC ΔflgKL and ΔfliC 
ΔflgKL ΔmotAB backgrounds (p < 0.05). In contrast, dele-
tion of motAB alone seems to reduce FlhA levels (0.75-
fold; p < 0.01). Overall, it is evident that the absence of 
clpX in strains upregulates FlhA levels, and by exten-
sion, other class II and III genes, which may explain the 
improvements to secretion we observed.
Improvements to secretion eiciency by secretion signal 
modiication
In parallel to the studies aimed at strain engineering for 
increased FT3SS capacity, we also examined the inlu-
ence of the secretion signal employed in the plasmid-
based modular secretion vector. he reasoning here 
was that the literature reports that the inclusion of the 
irst 47 residues of FliC [70], the 5′ and 3′UTRs [29, 30, 
35], or a truncated FliC 26–47 construct with either 
the Salmonella or E. coli version of residues 26–28 [34, 
35], can direct export of protein through a truncated 
FT3SS. All secretion construct (denoted SC) variants 
were inserted in frame with the cutinase gene, with the 
predicted size in kDa shown (Fig. 6). hese studies were 
conducted using the prototype ∆fliC ∆flgKL strain, 
with a ∆flhDC strain and empty vector as negative con-
trols. Expression of the prototype secretion construct 
(labelled as SC0 here) in the Mark II ∆fliC ∆flgKL ∆clpX 
strain served as an additional positive comparator. he 
data show that while all constructs produced cuti-
nase (Fig.  7a), some constructs neither expressed nor 
secreted well (SC3, 5, 7), while others had low intracel-
lular but signiicantly higher secreted levels of cutinase 
(SC1, p < 0.005), or, signiicantly high intracellular cuti-
nase (p < 0.001) with none secreted (SC8) (see Fig. 7b). 
From these data it is possible to infer that the 3′UTR—
while putatively inluencing intracellular stability of 
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Fig. 3 Protein secretion through the truncated FT3SS can be both 
controlled and improved. E. coli MC1000 ΔfliC ΔflgKL (ΔCKL or 
‘prototype’), ΔflhDC, ΔfliC ΔflgKL ΔflgDE (ΔCKL-DE) or ΔfliC ΔflgKL 
ΔclpX (ΔCKL-X or ‘Mark II strain’) containing pTrc-FliC-ΔD3 was grown 
with 0.05 mM IPTG (or 1 mM to allow overexpression in ΔflhDC) and 
harvested at  OD600 1.0. Secreted and intracellular cell fractions were 
loaded for SDS-PAGE in the quantities described in Fig. 2. A FliC-ΔD3 
protein standard was included to allow quantiication. Samples 
underwent a Coomassie staining or immunoblot analysis of cells and 
supernatant using b anti-lagellin (αH48) or c anti(α)-GroEL primary 
antibodies and a HRP-conjugated secondary
Page 7 of 17Green et al. Microb Cell Fact           (2019) 18:10 
cutinase-seems to actually reduce export (SC3, 5, 7). 
Whereas the intact 5′UTR and FliC 1–47 alone (SC1) 
seem to permit the highest levels of secretion, as this 
exports cutinase at 1.8-fold higher concentrations than 
the prototype (SC0). his led us to examine the pos-
sibility that the FliC 5′UTR alone, has the ability to 
direct secretion-as has been indicated by other work-
ers [30]. However, when we inserted the cutinase gene 
into plasmids containing only the 5 and 3′UTRs (SC10) 
or the 5′UTR alone (SC11), we observed that despite 
good expression in all strains (Additional ile 1: Fig. S7), 
cutinase secretion was at least fourfold lower (Fig. 7c). 
With this evidence, the plasmid harbouring SC1 was 
taken forward (for the construction of a Mark IV secre-
tion strain) as the best candidate for increased secre-
tion through the FT3SS.
Conirmation that the ‘late’ FliC signal outperforms 
an ‘early’ hook‑cap signal
As a inal step to investigate the optimal secretion signal, 
we compared secretion of our ‘late’ FliC signal with early 
lagellar substrate signal sequences, namely the hook 
(FlgE) and hook-cap (FlgD) proteins. In order to compare 
these signals, we constructed cutinase harbouring secre-
tion signal sequence variants using the irst 100 amino 
acids of FlgD or FlgE (Additional ile  1: Fig. S8a) for 
testing in both an early-locked, hook-less [ΔfliC ΔflgKL 
∆flgDE (∆clpX)], and a substrate switched [ΔfliC ΔflgKL 
(ΔclpX)] background. he FlgE signal did not permit 
secretion in either strain, and the FlgD signal was four- to 
ivefold less efective at export than the FliC signal (Addi-
tional ile  1: Fig. S8b). his indicated that despite the 
streamlined nature of the hook-less strain, it is in fact less 
eicient for secretion than the HAP-less strain. We did 
observe low-levels of cutinase secretion with SC13 (FlgD 
signal) in the ΔfliC ΔflgKL ΔclpX strain, presumably due 
to higher expression of secretion apparatus, but still at a 
much lower level (fourfold) than with the intact FliC sig-
nal (SC1).
Examination of combined strain and secretion signal 
improvements
Finally combination of the improvements to the chassis 
and modular secretion vector were investigated in com-
parison to the prototype versions. Both strains contained 
Fig. 4 Development of a high throughput luorescence assay 
to measure protein secretion through the truncated FT3SS. The 
‘prototype’ E. coli MC1000 ΔfliC ΔflgKL (ΔCKL) containing either 
pJex-fliC47-cutinase or pJex-fliC47-empty were grown as described 
in Fig. 3 and prepared for a immunoblot with the anti-FLAG-HRP 
(αFLAG) antibody (where samples representing either 15 µL or 300 µL 
culture media for intracellular and secreted protein respectively were 
loaded onto the SDS-PAGE) (b) or lorescence assay: 40 µL supernatant 
was added to 160 µL MUB substrate in a 96 well plate. Following 
incubation for 30 min at 30 °C, samples were visualised under UV light. 
c, d E. coli strains ΔfliC ΔflgKL (ΔCKL or ‘prototype’), ΔfliC ΔflgKL ∆clpX 
(ΔCKL-X or ‘Mark II strain’), ∆flhDC and ΔfliC ΔflgKL ∆flgDE (ΔCKL-DE) 
harbouring the cutinase expressing or empty vector plasmid were 
grown and c prepared for MUB secretion assay as described above; 
however following incubation, luorescence was measured in a 
plate reader (excitation 302 nm, emission 446 nm). Results from one 
biological replicate, with three technical repeats. ± SE and individual 
data points shown. Two-way ANOVA (variables: strain and plasmid) 
and Tukey’s multiple comparison test: ****p < 0.001. d Representative 
immunoblot of secreted and intracellular fractions prepared from the 
same cell cultures
◂
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more intracellular cutinase following expression of SC1 
over the SC0 prototype (Fig. 8a). Additionally there was 
more intracellular cutinase in the Mark III strain than 
the prototype-irrespective of secretion construct. Detec-
tion of the FLAG-tag by immunoblotting allowed visu-
alisation of secreted cutinase by a means other than the 
MUB assay. In agreement with previous results (Fig. 5a, 
b), the Mark III strain secreted a higher concentration of 
substrate in comparison to the ΔfliC ΔflgKL strain when 
expressing the prototype secretion construct (Fig. 8b, d), 
this translated to a 3.83-fold improvement in secretion 
eiciency (Fig.  8a, b). However, the highest concentra-
tions of secreted cutinase were seen when either strain 
expressed SC1, with ΔfliC ΔflgKL ΔclpX ΔmotAB result-
ing in the highest. Given the low abundance of GroEL in 
ΔfliC ΔflgKL ΔclpX ΔmotAB cell supernatant (Fig.  8c), 
we show that the increase in extracellular cutinase in 
this modiied strain is not due to cell lysis or membrane 
leakage. In fact the lower level of cytoplasmic leakage in 
ΔfliC ΔflgKL ΔclpX ΔmotAB suggests that the clpX allele 
may in fact destabilise the cell envelope, although this 
would require further investigation. We also note that 
the α-GroEL antibody is very sensitive and the Coomas-
sie stained gel (not shown) did not indicate cell leakage 
in the ΔfliC ΔflgKL strain either. Using the same sam-
ples, a MUB protein secretion assay was carried out 
(Fig.  8e). he improvement attributed to the optimised 
strain (ΔfliC ΔflgKL ΔclpX ΔmotAB) was 7.68-fold, and 
for the secretion construct (SC1) 15.70. Upon combina-
tion (Mark IV strain) these improvements were addi-
tive, resulting in a 23.78-fold increase in luorescence in 
comparison to the prototypes (all p < 0.001). Densitom-
etry analysis of secreted cutinase measured by immu-
noblotting (Fig.  8a, b), showed that the strain was 5.64 
times more eicient at secreting cutinase than the proto-
type. Despite immunoblotting determining the combined 
fold change in the Mark IV strain to be less pronounced 
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Fig. 5 Screening for strains which are high capacity secretors of 
recombinant cutinase, and additional substrates. a The ‘prototype’ E. 
coli MC1000 ΔfliC ΔflgKL (ΔCKL) strain with additional combinations 
of: ΔmotAB (mot) ΔflgMN (MN) ΔfliDST (DST) or ΔclpX (X), which 
contained pJex-fliC47-cutinase were grown with 0.05 mM IPTG 
and harvested at  OD600 1.0. Secreted fractions (Sn) were analysed 
by the MUB lorescence assay as described in Fig. 4c. Results from 
three biological replicates were normalised to ΔCKL, ± SE shown, 
one-way ANOVA: p ≤ 0.001. Tukey’s multiple comparison test to 
ΔCKL: *p ≤ 0.05, **p ≤ 0.01. Representative immunoblot of the 
intracellular fraction from 15 µL cell culture shown below. b E. coli 
ΔCKL (‘prototype’), ΔCKL-X-mot (Mark III strain) and ΔCKL-mot-DST 
expressing pJex-fliC47-CH2 (+, upper), pTrc-FliC-ΔD3 (+, lower), 
or empty vector (−) were grown (as above) and prepared for 
immunoblot using either an anti-FLAG-HRP (αFLAG) antibody 
(upper) or an anti-lagellin (αH48) antibody and a HRP conjugated 
secondary (lower). The equivalent of 15 µL cell culture was loaded 
for intracellular fractions, and either 300 or 60 µL for the secreted 
fractions (for  CH2 and FliC-ΔD3 respectively), along with the relevant 
protein standard to allow quantiication. c Whole cell fractions 
underwent immunoblot with an anti-FlhA antibody (αFlhA), results 
from densitometry are presented relative to ΔCKL. Five biological 
repeats, ± SE and individual data points shown. One-way ANOVA: 
p < 0.005 and Tukey’s multiple comparison test: *p < 0.05, **p < 0.01
▸
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(Fig.  8d), the overall trend is consistent with the MUB 
luorescence assay (Fig.  8e). he Mark IV strain had an 
average titre of 0.16  mg  L−1 secreted cutinase (highest 
0.19 mg L−1) (Fig. 9).
Testing secretion of a range of recombinant proteins 
of human origin
Finally we investigated secretion of a number of phar-
maceutically relevant, human proteins in the Mark IV 
FT3SS strain. hese included E. coli codon optimised 
versions of, the aforementioned  CH2 ScFv fragment, and 
also human growth hormone (hGH) and thioredoxin 
(TrxA)—both of which were kindly gifted following an 
ongoing collaboration with FUJIFILM Diosynth Biotech-
nologies, UK. Genes were PCR ampliied with EcoRI and 
PstI restriction site ends and inserted into the SC1 har-
bouring plasmid. All were secreted into the media, with 
respective average titres of 0.25, 0.15 and 0.21  mg  L−1 
from an  OD600 1.0 culture (Fig.  9, Additional ile 1: Fig. 
S9).
Discussion
Despite the clear beneits to protein production, to 
date, true secretion of recombinant protein by bacterial 
expression systems into the media is only possible in the 
mg  L−1 cell culture range, even in high density culture 
[19–21]. For commercial use this requires improvement, 
especially when compared to eukaryotic expression 
organisms—such as Pichia which can reach 15 g L−1 [22]. 
We focus on an E. coli chassis, due to its preferential use 
in IB, for a host of beneicial reasons. In this study, we 
set out to engineer an E. coli with the ability to secrete 
recombinant protein into the extracellular media, in one 
direct step. A clear candidate for this was the one step 
FT3SS, and while recombinant protein has been secreted 
through the FT3SS previously [29–31, 34, 36], we aimed 
to make improvements to improve secretion capacity, 
without leakage, though strain engineering and design of 
a modular secretion and puriication system.
We established that a prototype ∆fliC ∆flgKL strain 
outperformed a ∆fliCD strain (as utilised in other stud-
ies [29–31], in both protein production and secretion 
(Fig.  1). One explanation might be that FliD binds FliT, 
and so in the FliCD strain, more FliT is free to interact 
with, and suppress  FlhD4C2 activity, thus reducing FT3SS 
expression and secretion [61]. In contrast removal of 
FlgKL frees up the chaperone FlgN to promote transla-
tion-coupled secretion of FlgM-further raising expression 
of FT3SS components (including the fliC-UTR harbour-
ing modular secretion construct) [80], but whether this 
occurs in E. coli is not clear at present. We next inves-
tigated whether strain engineering could improve secre-
tion, and found that removal of clpX (a component of 
the ClpXP protease complex), which is known to actively 
bind to, and degrade  FlhD4C2 [64], improved the yield of 
Fig. 6 Schematic of secretion signal variants. The prototype secretion construct (SC0), and variations (SC1–SC11. Note that SC1 contributes to the 
‘Mark IV’ improvement) are depicted along with the predicted size of the protein product (kDa). All secretion constructs harbour cutinase, along 
with combinations of the 3′UTR, 5′UTR, the 1–47 residue FliC secretion signal, or the truncated secretion signal (residues 26–47) with the native E. 
coli or S. typhimurium codon usage. Construction of these plasmids is outlined in Additional ile 1: Fig. S5 and Table S2
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secreted FliC by 1.6-fold, to 34 mg FliC-ΔD3 L−1 culture 
medium at  OD600 1.0 (Fig. 3). his became our Mark II 
strain. We also show total absence of FliC-ΔD3 in the 
secreted fractions of FT3SS null strains, along with very 
low abundance of cytoplasmic contamination (absence 
of GroEL) (Fig.  3). his observation is consistent for 
recombinant proteins (Fig.  4d). Furthermore we show 
that, in the absence of the FliC secretion signal peptide, 
protein is not exported (Fig. 7b, c and Additional ile 1: 
Fig. S7). Combined, this demonstrates that in our system, 
the truncated FT3SS shows excellent selectivity and that 
leakage is not prevalent.
Development of a high-throughput, enzyme based, 
secretion assay (Fig.  4) enabled us to screen a range 
of engineered strains and secretion signal constructs 
(Figs.  5, 7). As enzyme activity requires correct protein 
folding, the assay also highlights that secreted heterolo-
gous cutinase correctly folds in the extracellular media, 
thus allowing functionality. his is very attractive when 
considering the proposed biotechnological applications 
of this truncated FT3SS secretion platform. hrough this 
screen we established the ∆flgKL ∆fliC ∆clpX ∆motAB as 
the superior (Mark III) secretion strain (Fig.  5). Several 
lines of evidence supported that clpX deletion has a posi-
tive efect on secretion through the FT3SS [64–67]. Fur-
ther to this, we observed increased ilament production 
and motility in ΔclpX cells in a wild-type background 
(Additional ile 1: Fig. S4), suggesting increased lagellar 
gene expression. We conirmed this notion in our trun-
cated secretor strain, as more FlhA was detected in ΔclpX 
mutants (Fig. 5c), suggesting an increase in the number of 
basal bodies (secretion apparatus). In contrast, the con-
centration of FlhA was not increased in motAB mutants, 
indicating that improved secretion in these strains was 
not due to higher abundance of secretion apparatus. A 
probable explanation is that this strain has reduced drain 
Fig. 7 Comparison of expression and secretion in secretion signal 
variants. a, b The ‘prototype’ E. coli ΔfliC ΔflgKL (ΔCKL) harbouring 
either pJex-fliC47-empty or the secretion signal variants SC0–SC9 
(see Fig. 6), along with ΔflhDC and ∆fliC ∆flgKL ∆clpX (ΔCKL-X or 
‘Mark II strain’) expressing SC0 were grown and harvested as in Fig. 3. 
a Intracellular fractions were prepared for immunoblotting (plus 
densitometry analysis: representative image shown), and b secreted 
fractions for MUB secretion assay, as described in Fig. 4a and c 
respectively. Three biological repeats, normalised to ΔCKL-SC0, ± SE 
and individual data points shown. One-way ANOVA (for SC0–SC9 
expressing strains only) p < 0.001 and Tukey’s multiple comparison 
test (to ΔCKL-SC0): ****p < 0.001, ***p < 0.005. c The absence of 
the 47 residue FliC signal, with the presence of the fliC 5′UTR was 
investigated in ΔCKL, ΔCKL-X and ΔflhDC compared to SC1. Procedure 
as described for Fig. 7b. Two biological replicates, ± SE and individual 
data points shown
▸
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on the proton motive force [82, 83], which would usually 
provide energy to drive lagellar rotation [86, 87], but also 
has implications for secretion and growth.
We also established, surprisingly, that combining the 
fliDST mutation with the Mark III ∆flgKL ∆fliC ∆clpX 
∆motAB strain increased secretion of cutinase, but not 
other proteins (Fig.  5b), indicating that there may be 
some protein speciic factors in determining secretion 
capacity. In fact the removal of fliDST, or flgMN were 
generally not beneicial to secretion. his may be attrib-
uted to the fact that there are contrasting reports on the 
efect of FlgM(N) deletion on lagellar expression in the 
literature [50, 79]. his is complicated by the fact that, 
FliS also binds FlgM prior to fliA expression, suppress-
ing secretion of FlgM upon hook-basal body completion 
[88], while removal of FliDST per se has been shown to 
result in an increase in secreted FlgM [89]. In addition, 
FlgN is also implicated here, as a positive regulator of 
FlgM translation [80], further complicating this picture, 
and making these data both hard to predict and interpret.
We show that a construct containing the 5′UTR and 
FliC1–47 secretion signal (SC1) was the most eicient for 
secretion of recombinant proteins (Fig. 7b). In agreement 
with previous work [30, 33], we did not ind inclusion of 
the 3′UTR to be necessary for secretion—as an extension 
to this, we also show that exclusion of the 3′UTR dra-
matically increases secretion, despite potentially reduc-
ing internal levels (Fig. 7a). An explanation may be linked 
to the evidence that the 3′UTR inluences levels and 
Fig. 8 Cutinase expression and secretion: comparing the prototype, 
and most improved, strains and secretion constructs. The E. coli 
‘prototype’ ΔfliC ΔflgKL (ΔCKL) or ‘Mark III strain’ ΔfliC ΔflgKL ΔclpX 
ΔmotAB (ΔCKL-X-mot) expressing either the prototype (SC0), 
improved (SC1) modular secretion vector, or pJex–fliC47-empty 
(empty), were grown as described in Fig. 3. Note that ΔCKL-X-mot 
expressing SC1 is our ‘Mark IV strain’. Both intracellular and 
secreted fractions underwent immunoblot analysis using either, 
an anti-FLAG-HRP (αFLAG) antibody to detect a intracellular and b 
secreted cutinase, or c anti-GroEL and a HRP secondary antibody to 
detect cytoplasmic protein contamination. Samples representing 
15 μL and 300 μL cell culture were loaded for intracellular and 
supernatant samples, respectively. d Densitometry analysis 
was carried out on αFLAG probed, secreted fractions (Fig. 8b: 
representative image) of three biological replicates, normalised to 
ΔCKL-SC0, ± SE and individual data points shown. One-way ANOVA, 
p < 0.005 and Tukey’s multiple comparison test (to ΔCKL-SC0): 
***p < 0.005, **p < 0.01, *p < 0.05. e Supernatant was also prepared 
for MUB protein secretion assay as described in Fig. 4c. Six biological 
replicates, normalised to ΔCKL-SC0, ± SE and individual data points 
shown. Two-way ANOVA, p < 0.001 and Tukey’s multiple comparison 
test (to ΔCKL-SC0): ****p < 0.001
▸
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stability of the fliC mRNA [90], which in turn has been 
shown to reduce FlgM secretion [67]. If this is afected 
by the 3′UTR region speciically, then this could explain 
improved secretion in the absence of the 3′UTR, as FlgM 
might be more readily secreted from the FT3SS—how-
ever at this time we have no evidence to support this the-
ory. In contrast, the 5′UTR and FliC1–47 are able to both 
direct secretion and ensure adequate protein expres-
sion. One reason for this might be that the signal peptide 
confers some level of solubility or reduces formation of 
inclusion bodies—though again we have not tested this 
directly. Notably, our evidence (Fig. 7b, Additional ile 1: 
Fig. S7) does not match that of other reports where the 
FliC 5′UTR [30, 31], or 26–47 residues of the FliC signal 
alone [34, 35], direct eicient secretion in E. coli. Neither 
does it match evidence that the 5′UTR is not necessary 
for secretion [35], and we can only attribute these dif-
ferences to potential variances in strain background or 
experimental conditions. It would seem that modiica-
tion of the secretion signal had a larger efect on secre-
tion capacity than the strain improvements (15.70- and 
7.68-fold improvements respectively). Most compelling, 
was our inding that upon combination, these improve-
ments have an additive efect on the secretion capacity of 
the FT3SS (Fig. 8). he overall 23.78-fold improvement to 
cutinase secretion through the FT3SS is a step-forward 
in terms of moving towards an E. coli strain capable of 
high capacity secretion of recombinant protein into the 
extracellular media, in one step.
In our lab, the best secreted yield of protein achieved 
(with cell density  OD600 < 1.5) in our truncated FT3SS 
(maximum of 240 mg L−1, average 80–90 mg L−1, of FliC-
ΔDE3 secreted into the extracellular media), surpasses 
that reported for alternative E. coli systems, which also 
enable secretion into the media. For example in the T1SS: 
typically in the µg L−1 range, but up to 3 mg−1 OD unit 
cell culture at high cell density [23–28, 91] and FT3SS 
(ΔfliCD): up to 12  mg  L−1 (although under unspeciied 
high density cell culture conditions, [30]). We also exceed 
reported yields achieved for secretion into the E. coli 
periplasm by the type II secretion system at low cell den-
sity (30–60 mg L−1 [13, 14]), without the requirement for 
periplasmic extraction or the risk of proteolytic enzymes 
compromising protein quality.
However as we are proposing the use of our strain as 
a secretion platform in a biotechnological context, we 
inally set out to investigate the performance of the Mark 
IV strain when secreting a broad range of industrial and 
pharmaceutically relevant recombinant proteins. At 
low cell density  (OD600 1.0) we achieved average yields 
of 0.16, 0.25, 0.15 and 0.21  mg  L−1 for cutinase, a  CH2 
ScFv fragment, human growth hormone and thiore-
doxin respectively (Fig. 9). he secreted titres we report 
for heterologous protein are lower than those which we 
measure for native protein (FliC-ΔDE3). his was antici-
pated, as aside from a small truncation, FliC-ΔDE3 is a 
natural substrate of the FT3SS, whereas the heterolo-
gous proteins are non-native to both the organism and 
the secretion system. We acknowledge that our titres of 
heterologous protein are lower compared to other bac-
terial systems (where up to 50  mg  L−1 was achieved) 
[20, 21]. However our results are still compelling, given 
that (unlike the majority of literature examples) we have 
achieved these titres from (1) culture supernatant, (2) at 
low cell density in E. coli, and (3) showed excellent con-
trol of secretion to the extracellular space, with no evi-
dence for cell leakage. When comparing our inal Mark 
IV strain to other strains that meet the majority of these 
credentials, our current strain secretes around four times 
less heterologous protein than the best titre reported in 
the T1SS (cell density unclear) [27], and around 50 times 
less than an alternative FT3SS system (carried out at a 
higher cell density and with diferent proteins) [30].
To match these reported titres in the future, we aim 
to further boost the titres of secreted protein, with a 
modiied cell culture strategy and more strain engineer-
ing. For example, while our supernatant was harvested 
at a maximum cell density of  OD600 1.5; it is noted that 
transfer to high cell density culture  (OD600 > 180) can 
greatly improve yields [14]. Indeed we have begun to test 
these strains at higher cell density in bioreactors with no 
obvious growth defects (unpublished data). Finally, the 
modular secretion vector has not only been optimised to 
Fig. 9 Secreted titres of a range of substrates through the optimised 
Mark IV secretion strain. E. coli ΔfliC ΔflgKL ΔclpX ΔmotAB expressing 
plasmid based SC1 (Mark IV strains), with either cutinase,  CH2, hGH 
or TrxA cargo, were grown as outlined in Fig. 3 and prepared, along 
with a relevant protein standard (exception: cutinase, where a hGH 
standard was utilised), for immunoblot detection with anti-FLAG-HRP 
(αFLAG). The concentration of secreted protein was then quantiied 
by densitometry analysis. Two biological replicates (with the 
exception of hGH), ± SE and individual data points shown
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enable high levels of expression (with the removal of the 
3′UTR), and lexibility of protein cargo, but also serves 
as a versatile platform technology which could be easily 
adapted for speciic applications, i.e. by exchanging the 
puriication or antigen tags. We are currently focussing 
on how the modular secretion vector performs in terms 
of recovery of puriied protein, free of the accessory tags.
Conclusions
We have used a combinatorial approach, incorporating 
strain design and a genetic modular secretion vector, to 
achieve improved extracellular titres, of a range of bio-
technologically relevant protein products, by secretion 
through a truncated E. coli FT3SS. his may enable sim-
pliied downstream processing of higher quality product, 
free of cellular contaminants, all of which are of great 
interest to the biopharmaceutical and IB communities. 
Furthermore, this opens up the possibility of cell cul-
tures that secrete protein continuously, without the need 
to sacriice cell culture to retrieve protein product. Dur-
ing development of the truncated secretion construct, 
a number of indings provided new information on the 
roles of the secretion signal peptide and UTRs of FliC 
monomers. We also introduce a high-throughput assay, 
enabling quick and accurate measurement of the secre-
tion output of truncated FT3SS strains. We are currently 
using this in inverse genetic engineering approaches to 
identify factors that might boost secretion further. We 
suggest that the body of this work serves as a pilot fea-
sibility study, and are working on further improvements 
(high cell density culture, purifying recombinant protein 
from the media), with which we envision that our FT3SS 
secretion platform could become a forerunner for use in 
the production of biopharmaceuticals and IB products.
Materials and methods
Bacterial strains and growth conditions
E. coli MC1000 was used for the construction of all 
mutants in this work (Additional ile 1: Table S1). E. coli 
strain MG1655 clpX::Tn5(KmR) was kindly gifted by J. 
Green, University of Sheield and was used as a donor 
for transduction in the construction of clpX strains. 
Strains were grown in LB broth or on LB agar plates, 
supplemented with ampicillin (100 µg mL−1), chloram-
phenicol (25  µg  mL−1) or kanamycin (50  µg  mL−1) or 
Isopropyl β-d-1-thiogalactopyranoside (IPTG) (con-
centration stated in igure legends) as appropriate. 
Prior to assaying protein secretion by SDS-PAGE or 
enzymatic secretion assay, fresh media was inoculated 
with cells from a liquid overnight culture and induced. 
Bacteria were grown with shaking at 180 rpm, 37 °C.
P1 phage transduction
Phage transduction was carried out by the method out-
lined by Lennox [92]. Following strain construction, 
the eradication of phage from the strain was ensured 
by passaging on LB agar plates with 10  mM sodium 
citrate. Absence of phage was then conirmed by Evans 
Blue-Uranine assay, as outlined by Tiruvadi Krishnan 
et al. [93].
Recombinant DNA techniques
Plasmids utilised for chromosomal manipulations or 
for cloning are listed in Additional ile 1: Table S2. High 
idelity and diagnostic polymerase chain reaction (PCR) 
was carried out with Phusion High Fidelity polymer-
ase (New England Biosciences) and DreamTaq DNA 
Polymerase (hermo Scientiic) respectively. Tem-
plates and custom primers (Sigma-Aldrich) are listed 
in Additional ile  1: Table  S3. Chromosomal modiica-
tions were carried out, as described by Datsenko and 
Wanner [94]. To enable sequential mutagenesis, pCP20 
was utilised to excise FRT lanked antibiotic resistance 
cassettes. Modiications were PCR veriied, as was the 
maintenance of other lesions on the chromosome, if the 
strain underwent sequential deletions.
A genetic secretion construct was designed, synthe-
sised and then incorporated into the pJexpress-404 
plasmid backbone by DNA 2.0. his plasmid is referred 
to as pJex-fliC47-empty (Additional ile  1: Fig. S4a) 
and forms the base cloning vehicle here. All restric-
tion digests and ligation reactions were performed with 
NEB restriction enzymes and T4 DNA ligase (New 
England Biosciences). Following ligation, reaction 
mixes were transformed into NEB 5-alpha (New Eng-
land Biosciences), as described in the supplier’s instruc-
tions. he synthetic gene for Fusarium solani cutinase 
(accession number: K02640), was codon optimised and 
synthesised by  GeneArt® Strings DNA Fragments (Life 
Technologies). hGH and TrxA gene fragments were 
obtained from FUJIFILM Diosynth Biotechnologies.
SDS‑PAGE and western immunoblots
Following cell growth for secretion, 1 OD unit of culture 
samples were centrifuged for 15 min (16,000g) to ensure 
separation of cells and supernatant. Supernatant fractions 
were prepared by precipitation in 10% v/v trichloroacetic 
acid and washing in acetone [57, 95]. Both supernatant 
precipitate and cell pellets were suspended in 2× SDS 
bufer (10  mL glycerol, 1  g SDS, 0.1  g bromophenol 
blue, 200  mM DTT, to a volume of 50  mL in 100  mM 
Tris–HCl, pH 6.8) to a inal volume of 50 µL and 200 µL 
respectively. Both cell lysate and supernatant samples 
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underwent SDS–polyacrylamide gel electrophoresis 
(SDS-PAGE). Gels were either stained with InstantBlue™ 
(Expedeon) or prepared for Western immunoblotting 
by electro-transfer onto nitrocellulose membrane (GE 
Healthcare Life Science) and blocked in 3% w/v bovine 
serum albumin in TBS (24 g L−1 Tris base, 88 g L−1 NaCl 
plus 0.1% v/v Tween). he following primary antibodies 
were diluted 1 in 1000 in TBS/Tween: H48 monospeciic 
H rabbit antiserum (Statens Serum Institut), monoclonal 
ANTI-FLAG®M2 antibody produced in mouse (Sigma-
Aldrich), E. coli GroEL rabbit IgG (Sigma-Aldrich). If 
required, following washing and re-blocking, anti-rab-
bit HRP (Cell Signalling Technology) was diluted 1 in 
3000. All blocking and incubation steps were carried 
out for 1  h. Immunoblots were visualised using  Pierce® 
ECL Western Blotting Substrates (hermo Scientiic) 
and a Compact X4 X-ray Film Processor (Xograph) or 
C-DiGit® Chemiluminescent Western Blot Scanner (LI-
COR Biosciences). Analysis by densitometry was carried 
out using ImageJ. For FlhA detection, the same proto-
col was followed except blocking was carried out in 5% 
w/v skimmed milk in PBS (8 g L−1 NaCl, 0.2 g L−1 KCl, 
1.44 g L−1  Na2HPO4, 0.24 g L
−1  KH2PO4) with 0.05% v/v 
Triton X100. Polyclonal anti-FlhA antisera was diluted 1 
in 1000 in PBS/Triton along with E. coli ΔflhDC soluble 
cell lysate (to minimise non-speciic binding) and follow-
ing washing, membranes were incubated with a 1 in 5000 
dilution of IRDye 800CW Donkey anti-rabbit secondary 
antibody (LI-COR Biosciences). Membranes were ana-
lysed using an Azure c500 (Azure Biosystems) imaging 
system and quantiied with LI-COR Image Studio Lite 
(LI-COR Biosciences).
Protein puriication for preparation of standards
To prepare puriied monomers of truncated FliC, 
MC1000 ΔfliC harbouring pTrc-FliC-ΔDE3 were scraped 
from semisoft agar plates (1% w/v tryptone, 0.5% NaCl, 
0.8% w/v bacteriological agar), following 24  h incuba-
tion at 37 °C. After resuspension in 50 mM Tris–HCl, pH 
7.8, cells were agitated vigorously in a laboratory blender 
(Waring Laboratory Science) for 3 min, then centrifuged 
at 16,000 g for 5 min at 4  °C. he supernatant was then 
centrifuged at 67,500 g for 15 min at 4 °C. he pellet was 
resuspended in fresh bufer, and centrifugation repeated. 
In fresh bufer, the pellet underwent sonication for 20 s, 
followed by heating to 50 °C for 10 min to cause monom-
erisation. Finally, centrifugation was repeated and super-
natant collected.
Protein standards of  CH2, TrxA and hGH were puriied 
from the intracellular fraction of E. coli BL21 (DE3) after 
induction with 1  mM IPTG. Protein was puriied using 
the secretion construct incorporated Streptavadin II tag 
on a 1  mL StrepTrap™ HP column (GE Healthcare Life 
Science) according to the manufacturer’s instructions. 
Following elution with 2.5  mM desthiobiotin, 100  mM 
Tris–HCl, 150  mM NaCl, 1  mM EDTA, pH 8, protein 
underwent dialysis overnight to yield puriied protein in 
100  mM Tris–HCl, pH 8 and quantiied with a Pierce™ 
BCA Protein Assay Kit (hermo Scientiic). Proteins 
standards were aliquoted and stored at − 20 °C.
Cutinase based protein secretion assay
An assay based on cleavage of 4-methylumbelliferyl 
butyrate (MUB) was developed to measure the activity 
of secreted cutinase. 10  mL cultures of cells expressing 
cutinase were induced with 0.05  mM IPTG and grown 
to  OD600 1.0. 250  mM MUB (prepared fresh daily) was 
dissolved in dimethylformamide with 1% Triton X-100. 
his mixture was then diluted in 50 mM phosphate cit-
rate (pH 5) bufer to a working concentration of 500 μM 
MUB. 40 μL supernatant was added to 96 well plate wells, 
the reaction was initiated with the addition of 160  μL 
MUB and incubated at 30 °C for 30 min. Following incu-
bation, luorescence was measured, either by imaging 96 
well plates under UV light (G:BOX, Syngene), or using 
a Tecan Ininite 200 Pro plate reader-excitation 302 nm, 
emission 446 nm (Tecan Group Ltd.).
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